Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B577a22471896eb11c77cb9a3b01e33dc> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B577a22471896eb11c77cb9a3b01e33dc NCIT_P378 "NCI" @default.
- B577a22471896eb11c77cb9a3b01e33dc type Axiom @default.
- B577a22471896eb11c77cb9a3b01e33dc annotatedProperty IAO_0000115 @default.
- B577a22471896eb11c77cb9a3b01e33dc annotatedSource NCIT_C118571 @default.
- B577a22471896eb11c77cb9a3b01e33dc annotatedTarget "An antibody-drug conjugate (ADC) composed of telisotuzumab, a monoclonal antibody against the tumor-associated antigen (TAA) and proto-oncogene, c-Met receptor tyrosine kinase (c-Met; MET; hepatocyte growth factor receptor; HGFR) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (vc) peptide linker (vc-MMAE; vedotin), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of telisotuzumab vedotin targets and binds to c-Met expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis." @default.